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Background: First line management of severe asthma exacerbations include the use of inhaled short-acting 
beta agonists, anticholinergics and systemic corticosteroids. Continuous intravenous ketamine given at 
dissociative doses may be a pharmacological option in patients who are intubated with life-threatening 
severe bronchospasm unresponsive to standard therapy.  
Case description: We describe the case of a 44-year-old male admitted to the intensive care unit (ICU) for 
status asthmaticus requiring intubation and mechanical ventilation. The patient developed severe refractory 
hypercapnic respiratory failure necessitating additional respiratory support with veno-venous 
extracorporeal membrane oxygenation (VV ECMO) therapy. Ketamine was initiated at 0.5 mg/kg/hour 
continuous infusion on the day of admission for pain control and required up-titration to 2 mg/kg/hour by 
ICU day four for bronchodilation. Whole blood samples were obtained for pharmacokinetic analysis of 
ketamine during ECMO.  
Results: The plasma concentration at steady-state was 1018.7 ng/mL with an estimated clearance of 1.96 
L/hour/kg following up-titration. The estimated volume of distribution, elimination rate and half-life was 
14.18 L/kg, 0.14 hr-1 and 5 hours, respectively.  
Discussion: Compared to healthy adults, there was a 6.5-fold increase in the volume of distribution. 
However, the volume of distribution was similar compared to non-ECMO critically ill patients. Further 
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Asthma exacerbation is one of the leading primary diagnoses in the emergency department (ED) 
accounting for 1.7 million visits annually in the United States.1 An estimated 25% of those patients 
encountered in the ED for asthma will be hospitalized with approximately 10% of those admitted to an 
intensive care unit (ICU).2 Although first-line treatments with oxygen, systemic corticosteroids, and 
bronchodilators are sufficient in reducing the symptomatology and airflow obstruction in most patients, 
approximately 3-5% of those admitted to the ICU will develop respiratory failure requiring intubation and 
mechanical ventilation.3 Extracorporeal membrane oxygenation (ECMO) therapy is a salvage therapy for 
severe acute asthma exacerbation when ventilation cannot be maintained with maximal medical therapies 
including deep sedation and neuromuscular blockade.  
Ketamine is a dissociative anesthetic capable of inducing analgesia at low doses and both analgesia 
and anesthesia at higher doses. It exerts its effects by noncompetitively antagonizing the N-Methyl-D-
aspartate receptor within the limbic and cortex system thereby producing a cataleptic dissociated state. In 
bronchial smooth muscle, ketamine reduces bronchospasm and airway resistance due to its 
sympathomimetic properties in the airways.4 In patients presenting with severe status asthmaticus, case 
reports have described use of intravenous ketamine in pediatric and adults as a means to avoid mechanical 
ventilation with bolus doses of 0.1 to 2 mg/kg followed by a continuous infusion of 0.15 to 2.5 mg/kg/hour.5, 
6  
The impact of ECMO on ketamine pharmacokinetics have not been described. Factors such as 
critical illness, varying degrees of organ dysfunction, components in the ECMO circuit, and the 
physicochemical properties of drugs have been implicated to contribute to the pharmacokinetic variability 
in this population. Importantly, interactions between the individual drug and the components of the ECMO 
circuitry are substantial particularly for lipophilic protein-bound drugs.7 Given the lipophilicity of ketamine 
(LogP = 2.9)8, adsorption of drug into the ECMO circuitry may impact its systemic disposition in patients. 
As a result, individual drug distribution, drug clearance and volume of distribution may be altered due to 
adsorption or sequestration into the ECMO circuit.  
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We describe the pharmacokinetics of ketamine in a critically ill patient on ECMO therapy. 
Pharmacokinetic parameters of interest (concentration at steady state, volume of distribution, clearance and 
half-life) are estimated, compared to literature, and critically discussed.    
Case Report 
A 44-year-old African American male with a past medical history of uncontrolled moderate 
persistent asthma and hypertension, self-reported to be non-compliant, presented to an outside hospital with 
increasing shortness of breath unresponsive to a recent steroid prescription from his primary physician. His 
height and weight was 170 cm and 81 kg (ideal body weight = 65.9 kg), respectively. He was placed on 
bilevel non-invasive positive pressure ventilation for acute hypercapnic respiratory failure and quickly 
progressed to requiring intubation and invasive mechanical ventilation. A chest tube was placed for bilateral 
pneumothorax. Despite aggressive medical therapy including therapeutic neuromuscular blockade and 
ventilator strategies to maximize expiratory time and mitigate gas-trapping, ventilation could not be 
adequately maintained and the patient was placed on veno-venous (VV) ECMO via the right internal jugular 
vein using a 27 French Avalon cannula. The ECMO circuit consisted of a Quadrox PLS oxygenator, 
Rotaflow pump and tubing-set all coated in Bioline® (MAQUET Cardiopulmonary AG, Hirrlingen, 
Germany). In accordance with local protocol, midazolam and fentanyl was used for primary pain control. 
Ketamine was initiated as an adjunct for pain management as a continuous infusion on day zero at a rate of 
0.5 mg/kg/hour following ECMO start at an outside hospital. Pulmonary symptoms included reduced breath 
sounds and wheezing requiring bronchotherapy with nebulized budesonide and ipratropium/albuterol in 
addition to montelukast and high-dose intravenous methylprednisolone. A respiratory pathogen PCR swab 
taken upon admission was positive for parainfluenza virus type 3, and sputum cultures were negative for 
bacterial infection. After initiation of VV ECMO, he was started on ultra-low tidal volume ventilation with 
a tidal volume of 200 mL (4.5 ml/kg IBW) on volume-control ventilation. The PaCO2 was kept in 
physiologic range with a high sweep setting on the VV ECMO circuit. On ICU day two, nebulized 
arformoterol was added to the regimen and ketamine was up titrated to 1 mg/kg/hour. Ketamine was 
subsequently titrated to 2mg/kg/hour on ICU day four, targeting a dose for treatment of severe acute asthma 
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exacerbation. The patient’s hospital course was further complicated by Clostridium difficile colitis, 
ventilator associated pneumonia, Enterococcal sepsis, and gastroduodenal bleed. Over the course of ICU 
days eight through eleven, the wheezing and airway resistance significantly improved and his tidal volume 
on volume-control was increased to 330 mL by ICU day nine and reached 520 mL following ECMO 
decannulation. Figure 1A trends lung compliance and airway resistance over the course of ketamine 
infusion. Airway resistance was calculated as the difference between peak inspiratory pressure and plateau 
pressure divided by the flow rate. Pulmonary compliance was calculated as the ratio between the tidal 
volume and the difference between the peak inspiratory pressure and the positive end-expiratory pressure. 
All parameters were measured daily from the mechanical ventilator record and maintained by the 
respiratory therapist. The patient was decannulated from ECMO on ICU day thirteen and proceeded to 
tracheostomy on ICU day fifteen. His chest tube was removed the following day on ICU day sixteen. The 
ketamine infusion was gradually weaned and discontinued on hospital day twenty-seven. 
Following informed consent, arterial blood sampling for ketamine analysis was obtained. A sample 
was taken 41 hours after the initial ketamine infusion. Additional samples were taken at 16, 100, 208, and 
268 hours following ketamine up-titration on ICU day four. Ketamine plasma concentrations during the 
continuous infusion are shown in figure 1B together with the observed decline in airway resistance. Plasma 
ketamine concentrations were analyzed using a validated ultra-high performance liquid chromatography-
tandem mass spectrometry following the FDA Guidance on Bioanalytical Method Validation.9  
The average (range) steady-state concentration (Css) during high-dose ketamine infusion was 
1018.7 (953.5-1063.6) ng/mL. This value represents the average of the three plasma samples collected at 
approximately 20, 42, and 54 half-lives during the continuous infusion. Patient specific pharmacokinetic 
parameters, including the volume of distribution (Vd), total plasma clearance (CL), elimination rate constant 
(ke) and half-life (t1/2) were estimated during the infusion. Total clearance was estimated by dividing the 
rate of infusion by the steady-state concentration [CL = Dose (mg/kg/hour)/Css]. Based on a reported plasma 
half-life of 4.98 hours in ICU patients, steady-state was presumed to have been reached approximately 24 
hours following ketamine up-titration. As such, the first plasma sample collected (approximately 16 hours 
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after up-titration) was used to calculate a patient specific elimination rate constant together with the mean 
of the plasma concentrations obtained at steady state using the following equation:  
ke = -2.3/t * log (Css – Cp/Css) 
Where Cp is the plasma concentration taken at time t (first sample, 16 hours post up-titration) and Css is the 
steady-state ketamine plasma concentration during the continuous infusion. The estimated elimination rate 
constant was then used to calculate the volume of distribution using the relationship (R0/kel)/Css, where R0 
is the infusion rate. Plasma half-life was estimated using t1/2 = 0.693/kel. The pharmacokinetic parameters 
are described in table 1 together with values reported in ICU patients and healthy adult subjects.10, 11  
After clinical improvement from a severe acute asthma exacerbation, the patient was successfully 
decannulated off VV ECMO and discharged from the hospital thirty-three days after ECMO removal. His 
follow up visit to the outpatient clinic after hospital discharge revealed no complaint of shortness of breath 
and was reported to be well controlled with aformoterol, nebulized budesonide and ipratropium/albuterol, 
and montelukast. There were no self-reported psychiatric behavior abnormalities reported during the follow 
up visit.   
Discussion 
Ketamine has several pharmacokinetic and pharmacodynamic (PKPD) advantages for initial and 
maintenance management of life-threatening asthma exacerbations. As an inductive agent during rapid 
sequence intubation, the quick onset and short duration of action makes ketamine an ideal agent for 
emergency airway management. In addition to its sedative and analgesic properties, ketamine has 
sympathomimetic activity at the bronchial smooth muscle resulting in bronchodilation. These unique PKPD 
properties make ketamine a useful agent for the initial management of severe asthma exacerbations 
requiring intubation. In cases where patients presenting with severe asthma exacerbations unresponsive to 
conventional therapy requiring emergency intubation, ketamine was reported to improve clinical and 
laboratory values following repeated administration.12-14 Infusion doses associated with efficacy ranged 
between 0.75 – 3 mg/kg/hour.13-15 These reports may suggest a dose-dependent bronchodilatory response 
often not seen with subanesthetic doses used in acute pain management. At dissociative doses, patients may 
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be at risk for emergence phenomenon due to ketamine’s dose-related psychomimetic effects. Enhanced 
airway secretion and hypersalivation is also anticipated from autonomic stimulation and may be a potential 
downside to using ketamine.  
We observed improvement in the patient’s wheezing by the fifth day after initiating high-dose 
ketamine with a complete resolution of symptoms ten days post up-titration. Reduction in airway resistance 
with an increase in pulmonary compliance were also observed during that period. These observations 
however, should be interpreted cautiously. Symptomatic improvement may have been contributed by other 
concomitant medications and interventions during the course of clinical care. This includes therapeutic 
agents such as high-dose corticosteroids, anticholinergics, beta2-agonists, leukotriene receptor antagonists 
and paralytics. Lastly, improvement may also have been possible with time during ECMO therapy.  
Ketamine is commercially available as a racemic mixture. The pharmacokinetics of ketamine can 
be characterized by multi-compartment models. In healthy adults, the estimated volume of distribution, 
clearance and elimination half-life of racemic ketamine is 2.18 L/kg, 0.88 L/hour/kg and 3.27 hours 
following a short infusion, respectively.10 These parameters are largely altered in critically ill patients where 
the volume of distribution may increase by as much as 7.3 fold.11  
This case is the first to report the pharmacokinetics of high-dose ketamine given to a patient 
unresponsive to standard asthma therapy during ECMO. The steady-state concentration during the 
continuous infusion was 1018.7 ng/mL. This concentration represents the average of three samples obtained 
approximately 20, 42 and 54 half-lives during the high-dose ketamine infusion. The concentrations 
achieved align with previous reports in those receiving a 2 mg/kg/hour ketamine infusion administered over 
two hours.11 Interestingly, the estimated pharmacokinetic parameters using the steady-state concentration 
did not largely differ among ICU patients. Moreover, it was hypothesized that the Vd for ketamine during 
ECMO would have been increased due to its lipophilicity and potential interaction with the ECMO circuit. 
Aside from lipophilicity, individual protein binding may also have a higher likelihood for drug sequestration 
during ECMO. In an ex-vivo study comparing drug lipophilicity and protein binding in ECMO circuits, 
drugs with higher protein binding were observed to have greater loss in the circuit despite having similar 
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lipophilic profiles.7 Drugs having similar lipophilicity- such as ciprofloxacin and thiopentone (LogP = 2.3)- 
but have contrasting protein binding profiles (ciprofloxacin = 20-40%, thiopentone = 80%) were observed 
to have a mean loss of 4% and 88% in the circuit after 24 hours, respectively. Ketamine is lipophilic (LogP 
= 2.9) and is 10-30% bound to plasma proteins. The low protein binding of ketamine may in part explain 
the similar Vd observed in critically ill non-ECMO patients suggesting the possibility of minimal interaction 
between ketamine and the ECMO circuit.  
Apart from its lipophilicity, ketamine is also highly water soluble.8 Although our patient appeared 
overweight (body mass index = 28), the patient was muscular and likely had a higher proportion of lean 
body mass. In patients who are overweight or obese, the impact of weight on ketamine pharmacokinetics 
may not be significant. Despite its large Vd, ketamine is also highly soluble in aqueous medium which may 
allow adequate concentrations in plasma relative to dose regardless of weight. Together, these observations 
should be validated in controlled ex-vivo and clinical studies.   
Although therapeutic drug monitoring is not routinely performed for sedatives in the intensive care 
setting, the results from this report may be of use in understanding the dose-exposure relationship and the 
impact of the ECMO circuitry on ketamine pharmacokinetics. Such information can optimize dosing to 
ensure adequate safety and efficacy of ketamine when used during ECMO.   
Conclusion 
A continuous infusion of 2 mg/kg/hour produced a steady-state concentration of 1018.7 ng/mL. 
There was a 6.5-fold increase in the volume of distribution compared to healthy adults, however this 
increase was similarly observed in critically ill patients administered ketamine. Other pharmacokinetic 
parameters remained consistent as compared to non-ECMO patients in the ICU.  Dedicated 
pharmacokinetic studies will be needed to determine optimal dosing and the potential impact of ECMO on 
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Figure 1. Airway resistance, pulmonary compliance and ketamine concentrations.   
(A) A trend of airway resistance, pulmonary compliance and (B) concentration-response during ketamine infusion as a function of time. The 
vertical dashed line represents ketamine up-titration to 2 mg/kg/hour (ICU day four). The red arrows represents clinical observations during his 
course in the hospital. 
